Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2022. It further provides the marketed products' API manufacturer details for United States, Europe, China, and India.

The report also covers the emerging Phase III pipeline assets for Infantile Spasm including their detailed product profiles. Additionally, the report also highlights the future competitive landscape for Fabry Disease therapeutics.

Scope of the Report

  • A comprehensive coverage of Fabry Disease marketed products including product description, regulatory milestones, clinical trials, deals and partnerships have been elaborated in this report
  • Patent information around Fabry Disease marketed products in United States (US) and Europe (EU) has been highlighted
  • API manufacturers details for Fabry Disease marketed therapeutics in United States, Europe, China and India
  • Comprehensive coverage of the emerging therapies (Phase III) for Fabry Disease including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information
  • The report contains historical and forecasted global sales till 2022 for each marketed product and forecasted sales till 2022 for emerging Phase III products for Fabry Disease

Key Topics Covered

  1. Report Introduction
  2. Overview
  3. Causes
  4. Symptoms
  5. Pathophysiology
  6. Epidemiology
  7. Diagnosis
  8. Treatment
  9. Emerging Treatment Strategies
  10. Comparative Analysis of Marketed and Emerging Products
  11. Marketed Therapies
  12. Galafold: Amicus Therapeutics
  13. Product Description
  14. Regulatory Milestones
  15. Research and Development
  16. Product Development Activities
  17. Other Clinical Activities
  18. Product Details
  19. Europe
  20. Global Sales
  21. Global Active Pharmaceutical Ingredient Manufacturers for Migalastat
  22. United States
  23. China
  24. Patent Details
  25. (The list continues)
  26. Emerging Therapy - Phase III
  27. Future Competitive Landscape

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vfzdpx/fabry_disease?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs